Novo Nordisk & Emcure Pharma partner to introduce innovative weight-loss drug in India.
Novo Nordisk India and Emcure Pharmaceuticals have announced a strategic collaboration to launch Poviztra, a new weight-loss medicine in India, marking a significant milestone in combating the country’s growing obesity epidemic. Poviztra contains semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, designed for chronic weight management and reducing cardiovascular risks among adults with overweight or obesity when combined with lifestyle changes.
Innovative Mechanism and Target Audience
Poviztra works by regulating appetite and food intake, enabling patients to adhere to a calorie-restricted diet without feeling constantly deprived—a breakthrough compared to traditional weight-loss methods. The drug is indicated for adults with a Body Mass Index (BMI) of 30 or higher, or 27 with related health conditions. Clinical trials under Novo Nordisk’s global STEP and SELECT programs demonstrated that one in three participants lost over 20% of their body weight, alongside reduced risks for heart disease.
Market Impact and Growing Need
With India facing a surge in obesity—estimated to affect over 254 million people—the launch of Poviztra offers hope amid a severe public health challenge. Jay Thyagarajan, Senior Vice President, Region APAC at Novo Nordisk, emphasized:
“Obesity is a serious chronic disease affecting millions in India. This collaboration leverages our cutting-edge GLP-1 therapy and Emcure’s local expertise, aiming to make effective obesity treatment more accessible across the country.“
Emcure CEO Satish Mehta added, “Our deep understanding of India’s diverse geographic and demographic landscape positions us well to connect patients with this life-changing therapy.”
Significance and Future Outlook
This partnership improves distribution beyond metropolitan centers, especially targeting smaller cities and towns, where medical intervention for obesity is still nascent. The launch underlines a growing commitment by leading pharma companies to prioritize metabolic health, addressing not just weight but associated comorbidities like diabetes and cardiovascular disease.
Experts like Dr. Ambrish Mithal, Chairman & Head of Endocrinology, Max Healthcare, highlight the drug’s potential:
“Semaglutide enhances satiety and reduces cardiac events by 20% in overweight individuals with heart disease. This is transformative for India’s fight against obesity.
Looking ahead, with patent expirations opening the door for generic entries and the government pushing for local manufacturing through PLI schemes, the weight-loss pharmaceutical landscape in India is set for rapid evolution and broader accessibility.
-
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article. https://www.binance.com/register?ref=IHJUI7TF
-
777cb Is it fun? I want to pick it up but I’m not sure, haha. Click to start a good time777cb
-
It’s smart to verify ID for higher withdrawal limits – a key security step! Platforms like ssbet77 ph link are making that easier for Filipino players. Always prioritize account protection & responsible gaming, though! 🤔
-
Slots are fun, but responsible play is key! Seeing platforms like big bunny ph link focus on quick deposits (like GCash!) & easy verification is a good sign for Filipino players. It’s all about convenience, right? 😉
-
Hey guys, just stumbled upon playtimeappapk! Seems like a decent spot for some casual gaming. Anyone else tried it out? Let me know your thoughts!
-
It’s fascinating how randomness impacts our perception of “luck” – a core element in games! Seeing platforms like gogojili online casino prioritize security and user experience during account setup is a smart move for building trust. It’s more than just chance, it’s about a reliable system!
Leave feedback about this